New Amsterdam Pharma
John Smither brings extensive financial and operating management experience to NewAmsterdam Pharma's Board of Directors. Most recently, he served as the Chief Financial Officer (CFO) at Arcutis Biotherapeutics, where he was responsible for all financial aspects, including leading the company’s successful initial public offering and two capital raises. Prior to joining Arcutis, Mr. Smither acted as CFO for Sienna Biopharmaceuticals, and as interim CFO for Kite Pharma during its integration with Gilead. He has also served as CFO of Unity Biotechnology and of Kythera Biopharmaceuticals. In his various CFO positions, John oversaw multiple private and public financing rounds, including Kythera’s initial public offering, and initial IPO preparations at Sienna. Additionally, John has previously served on the Boards of several biopharmaceutical companies including Achaogen, Inc. and Dompé Biotec, SpA. He also currently serves as Director at both eFFECTOR Therapeutics and Applied Molecular Transport.
This person is not in the org chart
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.